Author: vulgavis

Benefits and challenges of psychedelic microdosing – as reported by microdosers

Benefits and challenges of psychedelic microdosing – as reported by microdosers

Posted by | Aug 13, 2019 | , , |

Psychedelics microdosing is the practice of consuming very small, sub-hallucinogenic doses of psychedelic substances, most commonly LSD or dried psilocybin-containing mushrooms. We ran a large observational study where microdosers reported the benefits and challenges they face when microdosing. The most commonly reported benefits were improved mood, focus, and creativity whereas the most commonly reported challenges were illegality, physiological discomfort, and other perceived challenges including the unknown risk-effect profile of microdosing due to a lack of scientific research. What is microdosing? When it comes to psychedelics, “microdoses” are doses low enough that the person taking the substance does not experience...

Read More
Robots and the workforce: understanding the research

Robots and the workforce: understanding the research

Posted by | Aug 12, 2019 | , , , , |

Photo by Adam Muse on Unsplash This is a guest post by authors Manav Raj and Robert Seamans, originally published on the SpringerOpen blog Artificial intelligence (AI) and robotics technology has been advancing rapidly over the past several years. For example, the AI Index reports that the number of papers, courses, and patents related to AI has grown dramatically over the past five years, and a recent paper published by the National Bureau of Economic Research reports that venture capital investment in AI startups has increased almost tenfold and the annual number of purchases of robots has tripled over...

Read More
A malaria elimination catch up- Algeria leads the way

A malaria elimination catch up- Algeria leads the way

Posted by | Aug 10, 2019 | , , , , , |

Algeria (image source: Creative Commons) Shortly after Bugbitten’s recent Malaria elimination: are we nearly there yet? we were elated to hear that Algeria has been certified as one of the 38 malaria-free countries. This makes Algeria the second country to join the list in 2019 after Argentina. Plasmodium falciparum electronmicrograph (source: wikicommons, authors Rick Fairhurst and Jordan Zuspann, National Institute of Allergy and Infectious Diseases, NIH) To achieve WHO-certification of malaria elimination, a country needs to prove there has been no local transmission of any of the human malaria species across the country for 3 consecutive years, and that...

Read More
Thrivership: a new model to support victims of abuse to move beyond surviving to thriving

Thrivership: a new model to support victims of abuse to move beyond surviving to thriving

Posted by | Aug 9, 2019 | , |

Why is this study important? Domestic violence and abuse (DVA) is a serious public health issue, threatening the health of individuals the world over. While men can also experience DVA, women are disproportionately affected. Around 30% of women worldwide who have been in a romantic relationship report having experienced violence at the hands of their partner, and in the UK a woman is killed by her current or former male partner every four days. What is thrivership? The purpose of our study was to explore the concept of ‘thrivership’ with women who have experienced DVA. Thrivership is an emerging...

Read More
European Headache Federation guidelines for the use of monoclonal antibodies in migraine prevention: from evidence to recommendations

European Headache Federation guidelines for the use of monoclonal antibodies in migraine prevention: from evidence to recommendations

Posted by | Aug 8, 2019 | , , , , |

© ustas / stock.adobe.com Raffaele Ornello What is the aim of the guideline and what is the European Headache Federation (EHF) hoping to achieve for patients and physicians? Several trials have tested the efficacy and safety of the new anti-CGRP monoclonal antibodies. The aim of the guideline was to summarize the available evidence and provide patients and physicians with indications for treatment with anti-CGRP monoclonal antibodies just before their commercialization. Would you like to pick out relevant examples to illustrate the importance of the guideline? When putting new treatments into clinical practice, one of the most important considerations is...

Read More

Categories